Novartis Heart Failure Drug Fails to Win FDA Panel Backing (1)

March 27, 2014 8:51 PM

24 0

Novartis AG (NOVN)’s experimental heart failure medication failed to win the backing of U.S regulatory advisers, creating a potential hurdle to the company’s plan to build a portfolio of cardiac therapies around the drug.

An 11-member advisory panel to the Food and Drug Administration voted unanimously today that the product, serelaxin, shouldn’t be cleared for sale. The FDA doesn’t have to follow the advice of its advisers and is scheduled to rule on the therapy’s approval by May 17.

Read more

To category page